Core Viewpoint - The company will hold an investor briefing on September 17, 2025, to discuss its 2025 semi-annual report and address investor inquiries [2][3][4]. Group 1: Meeting Details - The investor briefing is scheduled for September 17, 2025, from 15:00 to 17:00 [4]. - The meeting will take place at the Shanghai Stock Exchange Roadshow Center, accessible online [4]. - The format of the meeting will be an interactive online session [3][4]. Group 2: Participation Information - Investors can participate in the briefing by logging into the Shanghai Stock Exchange Roadshow Center on the meeting day [4]. - Questions can be submitted from September 10 to September 16, 2025, through the Roadshow Center website or via the company's email [4][5]. - The company will address commonly asked questions during the briefing [3][5]. Group 3: Company Representatives - Key representatives attending the meeting include the General Manager, Chief Financial Officer, Board Secretary, and an Independent Director [4].

Group 1 - The company Huada Zhi Zao announced its participation in the 2025 semi-annual performance briefing for the medical device industry on September 17, 2025 [2]

Group 1 - The company will hold a collective performance briefing for the medical device industry on September 17, 2025, from 15:00 to 17:00 [1][2] - The briefing will take place at the Shanghai Stock Exchange Roadshow Center and will be conducted in an online interactive format [2][3] - Investors can submit questions from September 10 to September 16, 2025, before 16:00, through the Roadshow Center website or via the company's email [3] Group 2 - Key personnel attending the briefing include the General Manager, Chief Financial Officer, Board Secretary, and an Independent Director [2] - After the briefing, investors can access the main content and details of the event through the Roadshow Center [3]

证券代码：688114 证券简称：华大智造 公告编号：2025-057 深圳华大智造科技股份有限公司 关于召开 2025 年半年度科创板医疗器械及医疗设备行业集 体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2025 年 9 月 10 日（星期三）至 9 月 16 日（星期二）16:00 前登录 上 证 路 演 中 心 网 站 首 页 点 击 " 提 问 预 征 集 " 栏 目 或 通 过 公 司 邮 箱 （MGI_IR@mgi-tech.com）进行提问。公司将在说明会上对投资者普遍关注的问 题进行回答。 深圳华大智造科技股份有限公司（以下简称"公司"）已于 2025 年 8 月 23 日发布公司《2025 年半年度报告》，为便于广大投资者更全面深入地了解公司 2025 年半年度经营成果、财务状况，公司将于 2025 年 9 月 17 日（星期三）下 午 15:00-17:00 参与由上海证券交易所主办的 2025 年半年度科创板医疗器械及医 疗设备行业集体业绩说明会，就投资 ...

Investment Rating - The investment rating for the company is "Buy" [1][2] Core Views - The company reported a revenue of 1.114 billion yuan in the first half of 2025, a year-on-year decrease of 7.90%, with a net profit attributable to shareholders of -104 million yuan [1][2] - The second quarter of 2025 showed a recovery with a revenue of 659 million yuan, a year-on-year decrease of 2.93%, and a net profit of 29.77 million yuan, marking a year-on-year increase of 130.62% [1][2] - The company expects revenue growth driven by increased sequencing instrument installations and reagent sales, with projected revenues of 3.368 billion, 4.011 billion, and 4.671 billion yuan for 2025, 2026, and 2027 respectively, reflecting year-on-year growth rates of 11.8%, 19.1%, and 16.5% [2][3] Summary by Sections Financial Performance - In the first half of 2025, the company achieved a gross margin of 52.85%, down 10.31 percentage points year-on-year, primarily due to intensified industry competition and changes in product sales structure [2] - The sales expense ratio was 29.99%, management expense ratio was 19.93%, and R&D expense ratio was 24.38% in the first half of 2025 [2] - The company anticipates improvements in profitability as it deepens its quality enhancement and efficiency strategies [2] Sequencing Business - The full-length sequencing business generated revenue of 894 million yuan in the first half of 2025, a year-on-year decrease of 12.15%, with over 700 full-length sequencers sold, marking a year-on-year increase of 60.35% [2] - The company has sold over 5,300 sequencing instruments globally as of June 30, 2025, establishing a solid foundation for future reagent sales growth [2] - Domestic market revenue for sequencing reached 593 million yuan, a year-on-year decrease of 13.56%, while overseas revenue was 301 million yuan, a year-on-year decrease of 9.23% [2] Profit Forecast - The company forecasts net profits of -94 million yuan, 70 million yuan, and 196 million yuan for 2025, 2026, and 2027 respectively, with year-on-year growth rates of 84.4%, 175.0%, and 178.9% [2][3]

Core Insights - On September 1, BGI Genomics experienced a decline of 1.56% with a trading volume of 349 million yuan [1] - As of June 30, BGI Genomics reported a revenue of 1.114 billion yuan for the first half of 2025, a year-on-year decrease of 7.90% [2] Financing and Margin Trading - On September 1, BGI Genomics had a financing buy-in amount of 40.41 million yuan and a net financing buy of 8.50 million yuan, with a total margin balance of 432 million yuan [1] - The current financing balance of 426 million yuan accounts for 2.83% of the circulating market value, indicating a high level compared to the past year [1] Shareholder and Institutional Holdings - As of June 30, the number of shareholders for BGI Genomics increased by 7.64% to 13,500, while the average circulating shares per person decreased by 7.09% to 15,766 shares [2] - The top ten circulating shareholders include notable ETFs, with the Huaxia SSE Sci-Tech 50 ETF holding 11.53 million shares, a decrease of 245,600 shares from the previous period [3]

重要内容提示： ? 本次股票上市类型为首发限售股份；股票认购方式为网下，上市股数为 本次股票上市流通总数为200,177,511股。 ? 本次股票上市流通日期为2025 年 9 月 9 日。 一、本次上市流通的限售股类型 经中国证券监督管理委员会《关于同意深圳华大智造科技股份有限公司首次 公开发行股票注册的批复》 （证监许可〔2022〕1638 号）同意，公司向社会公开发 证券代码：688114 证券简称：华大智造 公告编号：2025-056 深圳华大智造科技股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 行人民币普通股（A 股）41,319,475 股，并于 2022 年 9 月 9 日在上海证券交易所 科创板挂牌上市。公司首次公开发行 A 股前总股本为 371,790,525 股，首次公开发 行 A 股后总股本为 413,110,000 股，其中有限售条件流通股 381,217,890 股，无限 售条件流通股 31,892,110 股。具体情况详见公司于 2022 年 9 月 8 日在上海证券交 易所网站 ...

Core Viewpoint - The company Huada Zhi Zao announced the upcoming listing of its first public offering of restricted shares, indicating a significant event for its stock market presence [1] Group 1 - The type of stock listing is for the first public offering of restricted shares [1] - The total number of shares to be listed for circulation is 200,177,511 shares [1] - The date for the stock listing and circulation is set for September 9, 2025 [1]

证券代码：688114 证券简称：华大智造 公告编号：2025-056 深圳华大智造科技股份有限公司 首次公开发行部分限售股上市流通的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为首发限售股份；股票认购方式为网下，上市股数为 200,177,511股。 本次股票上市流通总数为200,177,511股。 本次股票上市流通日期为2025 年 9 月 9 日。 一、本次上市流通的限售股类型 经中国证券监督管理委员会《关于同意深圳华大智造科技股份有限公司首次 公开发行股票注册的批复》（证监许可〔2022〕1638 号）同意，公司向社会公开发 行人民币普通股（A 股）41,319,475 股，并于 2022 年 9 月 9 日在上海证券交易所 科创板挂牌上市。公司首次公开发行 A 股前总股本为 371,790,525 股，首次公开发 行 A 股后总股本为 413,110,000 股，其中有限售条件流通股 381,217,890 股，无限 售条件流通股 31,892,110 股。具体情况 ...

经中国证券监督管理委员会《关于同意深圳华大智造科技股份有限公司首次 公开发行股票注册的批复》（证监许可〔2022〕1638 号）同意，公司向社会公 开发行人民币普通股（A 股）41,319,475 股，并于 2022 年 9 月 9 日在上海证券 交易所科创板挂牌上市。公司首次公开发行 A 股前总股本为 371,790,525 股，首 次公开发行 A 股后总股本为 413,110,000 股，其中有限售条件流通股 381,217,890 股，无限售条件流通股 31,892,110 股。具体情况详见公司于 2022 年 9 月 8 日在 上海证券交易所网站（www.sse.com.cn）披露的《华大智造首次公开发行股票科 创板上市公告书》。 本次上市流通的限售股为公司首次公开发行前股东持有的部分限售股，涉及 限售股股东数量为 4 名，限售期限为自公司股票上市之日起 36 个月，该部分限 售股股东对应的股份数量为 200,177,511 股，占公司股本总数的 48.06%。现锁定 期即将届满，将于 2025 年 9 月 9 日起上市流通。本次解除限售后，相关股东将 履行其自愿承诺并实行自律管理。 二、本次上市流通 ...